Clinical trials: Children Behavior
- Condition Children Behavior
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17
The purpose of this study is to assess the safety and efficacy of SPD503 (Guanfacine hydrochloride) compared to placebo in the treatment of ADHD in children and adolescents aged 6-17
- Trial name
- NCT00152009
- Testing
- SPD503 (Guanfacine hydrochloride) (2 mg), SPD503 (3 mg), SPD503 (4 mg)
- Volunteers
- 345 people
- Sponsor
- Shire
ADHD
KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD
This study is a multicenter, dose-optimized, open-label safety study with KP415 in children with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT03460652
- Testing
- KP415 oral capsule
- Where
- 19 sites in United States
- Volunteers
- 282 people
- Sponsor
- Zevra Therapeutics
Attention Deficit Hyperactivity Disorder
A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD
This 6-week study is to determine if the study drug, Methylphenidate Hydrochloride (HCl) Extended-Release Chewable Tablets (ERCT), is safe, tolerable and effective when compared to a sugar pill or placebo in children 4 to 5 years…
- Trial name
- NCT03536390
- Testing
- Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder (ADHD)
Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD
Assess the efficacy \& tolerability of Vyvanse when children aged 6-12 years diagnosed with ADHD are dosed to optimal effect.
- Trial name
- NCT00500071
- Testing
- Vyvanse (lisdexamfetamine dimesylate)
- Where
- 46 sites in United States
- Volunteers
- 318 people
- Sponsor
- Shire
Parenting Practices, Self Efficacy
Evaluation Study of Talk Parenting Skills
After development of the prototype Bedtime Routine module of the Talk Parenting program, the investigators will evaluate its feasibility and initial efficacy in a within-subjects pre-post design study.
- Conditions
- Parenting Practices, Self Efficacy, Stress, Child Behavior
- Trial name
- NCT04633434
- Testing
- The Talk Parenting Skill for Alexa
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
ADHD
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD
This study will evaluate the efficacy and safety of high doses of SPN 812 in children with ADHD
- Trial name
- NCT03247543
- Testing
- 200mg SPN-812, 400mg SPN-812
- Where
- 10 sites in United States
- Volunteers
- 313 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit/Hyperactivity Disorder
An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD
This is a multicenter, dose-optimized, randomized, double-blind, placebo controlled, efficacy and safety study with Azstarys® in children 4 to 12 years of age with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- KP415P01 (NCT05685732)
- Testing
- Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
- Where
- 20 sites in United States
- Volunteers
- 246 people
- Sponsor
- Corium, Inc.
Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder
GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs
The purpose of this study is to examine the use of, and reaction to, one particular software application(GroundsKeeper) delivered on unique platform - Sifteo cubes (www.sifteo.com).
- Conditions
- Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Pervasive Developmental Disorder, Asperger's Disorder
- Trial name
- NCT01808066
- Testing
- Groundskeeper
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- CogCubed, Corp
Attention Deficit Hyperactivity Disorder
Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)
Atomoxetine versus placebo in Children with Attention-Deficit/Hyperactivity Disorder (ADHD)
- Trial name
- NCT00191295
- Testing
- Atomoxetine
- Where
- 24 sites in Japan
- Volunteers
- 240 people
- Sponsor
- Eli Lilly and Company
ADHD
Classroom Study of SPN-812 in Children With ADHD
This study will evaluate the efficacy and safety of SPN-812, an extended-release formulation of viloxazine, compared to placebo in children in an analog classroom setting.
- Trial name
- NCT04016792
- Testing
- 200 mg SPN-812
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit and Disruptive Behavior Disorders
A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
The purpose of this study is to assess the efficacy and safety of risperidone as maintenance therapy to prevent symptoms of relapse in children and adolescents with conduct and other disruptive behavior disorders, who initially…
- Trial name
- NCT00236444
- Testing
- risperidone
- Volunteers
- 375 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Attention Deficit Hyperactivity Disorder
Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia
There has been an increased interest in the association between ADHD and sleep disorders over the past years. A high incidence of sleep disturbance, ranging from 10% to 70%, has been identified in ADHD children regardless of…
- Trial name
- Zolkids (NCT00318448)
- Testing
- Zolpidem (SL800750)
- Where
- 2 sites in United States, Canada
- Volunteers
- 201 people
- Sponsor
- Sanofi
Attention Deficit Hyperactivity Disorder
Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this 12-month, multi-center, open-label study is to evaluate the safety of CLONICEL (clonidine HCl sustained release) when administered chronically under regular clinical conditions either as monotherapy or in…
- Trial name
- NCT00723190
- Testing
- CLONICEL (Clonidine HCl sustained release)
- Where
- 27 sites in United States
- Volunteers
- 303 people
- Sponsor
- Shionogi
Haemophilia A, Haemophilia B
A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia
The Hemophilia Growth and Development Study (HGDS) nearly 25 years ago showed haemophilia and HIV impacted brain development, thinking, and behaviour in children and adolescents.
- Trial name
- eTHINK (NCT03660774)
- Testing
- No treatment given
- Where
- 22 sites in United States
- Volunteers
- 563 people
- Sponsor
- Novo Nordisk A/S
Major Depressive Disorder
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
This is a double-blind study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) versus placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
- Trial name
- NCT01371734
- Testing
- Desvenlafaxine Succinate Sustained-Release
- Where
- 42 sites in United States, Chile and 1 more
- Volunteers
- 363 people
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder
CONCERTA Lab School Study
The purpose of this trial is to determine if the study medication, CONCERTA (methylphenidate HCl), is safe and effective in improving academic performance and behavior in children with Attention Deficit Hyperactivity Disorder…
- Trial name
- NCT00799487
- Where
- 3 sites in United States
- Volunteers
- 89 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Attention Deficit Hyperactivity Disorder
Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the long-term safety and effectiveness of OROS® Methylphenidate HCl (a central nervous system stimulant) in children with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT00269815
- Testing
- methylphenidate HCl
- Sponsor
- Alza Corporation, DE, USA
Obsessive-Compulsive Disorder
Child and Adolescent OCD Outcomes From Exposure and Response Prevention Video Teletherapy Treatment
This is a naturalistic, observational study of children and adolescents with obsessive-compulsive disorder who were treated with exposure and response prevention via video teletherapy.
- Trial name
- NCT06466447
- Testing
- Exposure and response prevention therapy
- Where
- United States
- Volunteers
- 2,173 people
- Sponsor
- NOCD
Attention Deficit Hyperactivity Disorder
Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
The purpose of this study is to evaluate the safety and efficacy of ORADUR®-Methylphenidate in children and adolescents with ADHD.
- Trial name
- NCT02450890
- Where
- 4 sites in Taiwan
- Volunteers
- 114 people
- Sponsor
- Orient Pharma Co., Ltd.
Attention-Deficit/Hyperactivity Disorder, Comorbid Dyslexia
Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
The purpose of this study is to assess the efficacy and safety of atomoxetine administered once daily in the treatment of children and adolescents with ADHD and comorbid dyslexia.
- Trial name
- NCT00191048
- Testing
- Atomoxetine
- Where
- 8 sites in United States
- Volunteers
- 105 people
- Sponsor
- Eli Lilly and Company